Role of continuing regular follow-up of serial B-human chorionic gonadotropin measurements with health education following initial surgical management of complete molar pregnancy cases

Research Article

Abstract views: 171 / PDF downloads: 69


  • Elmahaishi MS



complete molar pregnancy, serial B-HCG , persistent trophoblast disease


Objective: Our goal to confirm complete cure, early detection of persistent gestational trophoblastic disease and more effective and less complex treatment.

Methods: Fifty-one patients from 12,960 were admitted to the Department of Obstetrics and Gynecology at Tobruk Medical Center between August 2018 and July 2021 with complete molar pregnancy, the diagnosis was confirmed with histopathology after initial surgical management. Following identification of these patients, due to lack of registration centers, the patient's telephone was required to complete the data for continuing regular follow-ups over a period of time these patients were evaluated prospectively according to their age, number of deliveries, history of normal and abnormal pregnancy, the quantity of beta-human chorionic gonadotropin (B-HCG) at the time of diagnosis and follow-up and treatment type. Persistent gestational trophoblast disease was diagnosed on the basis of a rise of B-HCG after initial evacuation, and just one patient in our study diagnosed with invasive mole and underwent second evacuation and none of these patients developed choriocarcinoma during the follow-up period. Analysis was conducted by using the social package of statistical science (SPSS) version 25 software. 

Results: 51 patients (0.39%) were diagnosed with complete molar pregnancy (CMP), the mean age was 31.90 (8.169) years range (17-47 years). Among 51 patients with CMP over three years, seventeen patients (33.3%) were diagnosed with persistent gestational trophoblast disease (PGTD), the incidence is about 1.3 per 1000 per deliveries, thirty-four patients (66.7%) reached spontaneous remission of molar gestation in a median time of 61 days and had a total follow-up time of 24 months. 

Conclusion: Follow-up women with complete molar pregnancy especially after initial management is challenging task as the incidence of molar pregnancy increasing  and exposed to the risk of developing persistent gestational trophoblastic disease, and there are no specialist centres for documentation and surveillance programme. And due to wide geographical area in Libya and difficulty in the follow-up patients with molar pregnancies, especially after initial treatment has been performed. Therefore, we must create multiple centers throughout the country to cover all cases as much as possible and the communication between the patients and centers via internet, to ensure early detection of pregnancy complications.


Ngan S, Seckl MJ. Gestational trophoblastic neoplasia management: an update. Curr Opin Oncol 2007;19:486–91. doi:10.1097/ CCO.0b013e3282dc94e5

Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet 2010;376:717–29. doi:10.1016/S0140-6736(10)60280-2

Altieri A, Franceschi S, Ferlay J, Smith J, La Vecchia C. Epidemiology and etiology of gestational trophoblastic diseases. Lancet Oncol 2003; 4: 670-8. [CrossRef]

Ozalp SS, Yalcın OT, Tanır HM. Hidatiform mole in Turkey from 1932 to 2000. Int J Gynecol Obstet 2001; 73: 257-8. [CrossRef]

Almasi A, Almassinokiani F, Akbari P. Frequency of molar pregnancies in health care centers of Tehran, Iran. J Reprod Infertil. 2014;15:157–60. [PMC free article] [PubMed] [Google Scholar

Korevaar TIM, Steegers EAP, de Rijke YB, Schalekamp Timmermans S, Visser WE, Hofman A, et al. Reference ranges and determinants of total hCG levels during pregnancy: The Generation R Study. Eur J Epidemiol 2015;30:1057 66.

Wolfberg AJ, Berkowitz RS, Goldstein DP, Feltmate C, Lieberman E. Postevacuation hCG levels and risk of gestational trophoblastic neoplasia in women with complete molar pregnancy. Obstet Gynecol 2005;106:548 52.

Jagtap SV, Aher V, Gadhiya S, Jagtap SS1... Gestational trophoblastic disease Clinicopathological study at tertiary care hospital. J Clin Diagnostic Res 2017;11:EC27 30.

Bolze P-A, Attia J, Massardier J, et al. Formalised consensus of the European Organisation for Treatment of Trophoblastic Diseases on management of gestational trophoblastic diseases. Eur J Cancer. 2015;51(13):1725–1731. doi:10.1016/J.EJCA.2015.05.026 [PubMed: 26092638]

Ngan HYS, Seckl MJ, Berkowitz RS, et al. Update on the diagnosis and management of gestational trophoblastic disease. Int J Gynecol Obstet. 2018;143:79–85. doi: 10.1002/ijgo.12615 [PubMed] [CrossRef] [Google Scholar

RCOG. The Management of Gestational Trophoblastic Disease. Published online 2010. Accessed February 12, 2018.

Zhao P, Shuangyan W, Xiuli Z, Lu W. A novel prediction model for postmolar gestational trophoblastic neoplasia and comparison with existing models. Int J Gynecol Cancer 2017;27:1028 34.

Khoo SK, Baartz D, Sidhu M, Yip WL, Tripcony L. Analysis of risk factors for persistent gestational trophoblastic disease. Aust New Zeal J Obstet Gynaecol 2009;49:657 9.

Mousavi AS, Karimi S, Modarres Gilani M, Akhavan S, Rezayof E. Does Postevacuation β Human chorionic gonadotropin level predict the persistent gestational trophoblastic neoplasia? ISRN Obstet Gynecol 2014;2014:1 4.

D. P. Goldstein and R. S. Berkowitz, “Prophylactic chemotherapy of complete molar pregnancy,” Seminars in Oncology, vol. 22, no. 2, pp. 157–160, 1995.

J. F. Holland, M. M. Hreschchyshyn, and O. Glidewell, “Controlled clinical trials of methotrexate in treatment and prophylaxis of trophoblastic neoplasia,” in Proceedings of the Tenth International Cancer Congress, R. L. Clark, R. W. Curnley, J. E. McKay, and M. M. Copeland, Eds., pp. 461–462, Medical Arts Publishing, Houston, Tex, USA, 1970.

D. S. Kim, H. Moon, K. T. Kim, Y. J. Moon, and Y. Y. Hwang, “Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole,” Obstetrics and Gynecology, vol. 67, no. 5, pp. 690–694, 1986.

Alberta Health Services Clinical Practice Guideline Gyne-008 Gestational trophoblastic neoplasia June, 2012.

SOGC Guideline No. 408: Management of Gestational Trophoblastic Diseases, J Obstet Gynaecol Can 2021;43(1):91−105.




How to Cite

Elmahaishi MS. (2024). Role of continuing regular follow-up of serial B-human chorionic gonadotropin measurements with health education following initial surgical management of complete molar pregnancy cases : Research Article. American Journal of Medical and Clinical Research & Reviews, 3(1), 1–8.